Announcements Trials
Browse Landscape

Phase

Phase NA 13Phase 2 5Phase 3 1Phase 2/3 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdomyosarcoma 1

Interventions

pembrolizumab 221Carboplatin 214Cisplatin 202Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 113Cyclophosphamide 101Pemetrexed 100Dexamethasone 100Specimen Handling 98Oxaliplatin 96Magnetic Resonance Spectroscopy 96Radiotherapy 92Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 67durvalumab 65Lenalidomide 64atezolizumab 61Radiation 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Sentinel Lymph Node Biopsy × 1 year × Clear all
NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡